Additional file 1: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Additional file 1: of A comparison of analytic approaches for individual patient data meta-analyses with binary outcomes

Doneal Thomas (3269046)
Robert Platt (507752)
Andrea Benedetti (139371)

February 2017

Median (Interquartile range (IQR)) absolute bias (%) for treatment effect, Î˛1 for different approac...

Additional file 1: of The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study

Anna O’Connor (3117774)
Carter Thorne (3508292)
Hyeon Kang (3508295)
Diane Tin (786343)
Janet Pope (3464090)

August 2016

Comparison of mean change in outcome measurement scores between early period (0–6 weeks) and late pe...

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 3: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Rieke Alten (52012)
Harald Burkhardt (23413)
Eugen Feist (609857)
Klaus KrĂźger (4763949)
Juergen Rech (4763922)
Andrea Rubbert-Roth (358862)
Reinhard Voll (23411)
Yedid Elbez (4763928)
Christiane Rauch (4763931)

January 2018

is a table presenting safety profile data of csDMARDs administered in combination with abatacept in ...

Additional file 1: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S1. Adjusted mean change from baseline in SF-36 individual domains at weeks 16 (all patients) ...

Additional file 2: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S2. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...

Additional file 3: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...

Additional file 1: of Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Vibeke Strand (410780)
Laure Gossec (4058521)
Clare Proudfoot (5165081)
Chieh-I Chen (4415830)
Matthew Reaney (5424773)
Sophie Guillonneau (5424776)
Toshio Kimura (5424779)
Janet van Adelsberg (5424782)
Yong Lin (177139)
Erin Mangan (5424785)
Hubert van Hoogstraten (5079860)
Gerd Burmester (52016)

June 2018

Table S1. LSM changes in RAID individual domain scores from baseline to week 24 with sarilumab 200Â ...

Additional file 7: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

Mean change from baseline in HAQ-DI by visit (ITT population). Abbreviations: Adalimumab-EU adalimum...

Additional file 6: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

DAS28–4(CRP) of less than 2.6 and ACR/EULAR remission by study visit (ITT population). Abbreviations...

Additional file 3: of Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study

Joshua Wallach (4741575)
Oriana Ciani (4485976)
Alison Pease (4991474)
Gregg S. Gonsalves (731654)
Harlan Krumholz (3401270)
Rod Taylor (25312)
Joseph Ross (3435704)

March 2018

Table S1. Pivotal trials with at least one postapproval trial with a patient-relevant outcome. (XLSX...

Additional file 1: of A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Stanley Cohen (411535)
Rieke Alten (52012)
Hideto Kameda (3399878)
Tomas Hala (5567096)
Sebastiao Radominski (5567099)
Muhammad Rehman (5567102)
Ramesh Palaparthy (4951276)
Karl Schumacher (5567105)
Susanne Schmitt (5567108)
Steven Hua (5567111)
Claudia Ianos (5567114)
K. Sewell (5614937)

July 2018

Supplementary methods and results, supplementary figures and figure legends, and supplementary table...

Additional file 4: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Mark Genovese (3442910)
Rene Westhovens (11539)
Luc Meuleners (4996577)
Annegret Van der Aa (4996583)
Pille Harrison (4996580)
Chantal Tasset (4996586)
Arthur Kavanaugh (2683)

March 2018

Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical di...

Additional file 1: of Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

Flora Elwes (4805568)
Shyamanga Borooah (491949)
Peter Aspinall (4805562)
Peng Sim (4805571)
Cheng Loo (4805565)
Ana-Maria Armbrecht (4805574)
Baljean Dhillon (4001)
Peter Cackett (4805559)

January 2018

Supplementary data. Correlated component regression analysis examining the predictors of change in B...

Additional file 1: Table S1. of Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors

Marie-Laure Golinski (786439)
Thibault Vandhuick (3441770)
Céline Derambure (786435)
Manuel Fréret (786436)
Matthieu Lecuyer (3441773)
Clément Guillou (786434)
Martine Hiron (3441767)
Olivier Boyer (211211)
Xavier Le Loët (408285)
Olivier Vittecoq (408284)
Thierry Lequerré (786441)

December 2015

Clinical and biological characteristics of rheumatoid arthritis (RA) patients treated with adalimuma...

Additional file 1: of A comparison of analytic approaches for individual patient data meta-analyses with binary outcomes

Doneal Thomas (3269046)
Robert Platt (507752)
Andrea Benedetti (139371)

February 2017

Median (Interquartile range (IQR)) absolute bias (%) for treatment effect, Î˛1 for different approac...

Additional file 1: of The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study

Anna O’Connor (3117774)
Carter Thorne (3508292)
Hyeon Kang (3508295)
Diane Tin (786343)
Janet Pope (3464090)

August 2016

Comparison of mean change in outcome measurement scores between early period (0–6 weeks) and late pe...

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 3: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Rieke Alten (52012)
Harald Burkhardt (23413)
Eugen Feist (609857)
Klaus KrĂźger (4763949)
Juergen Rech (4763922)
Andrea Rubbert-Roth (358862)
Reinhard Voll (23411)
Yedid Elbez (4763928)
Christiane Rauch (4763931)

January 2018

is a table presenting safety profile data of csDMARDs administered in combination with abatacept in ...

Additional file 1: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S1. Adjusted mean change from baseline in SF-36 individual domains at weeks 16 (all patients) ...

Additional file 2: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S2. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...

Additional file 3: of Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Vibeke Strand (410780)
Evo Alemao (5070941)
Thomas Lehman (6059288)
Alyssa Johnsen (358784)
Subhashis Banerjee (327601)
Harris Ahmad (6059291)
Philip Mease (77706)

December 2018

Table S3. Proportion of patients (95% CI) treated with abatacept or placebo reporting improvements â...

Additional file 1: of Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Vibeke Strand (410780)
Laure Gossec (4058521)
Clare Proudfoot (5165081)
Chieh-I Chen (4415830)
Matthew Reaney (5424773)
Sophie Guillonneau (5424776)
Toshio Kimura (5424779)
Janet van Adelsberg (5424782)
Yong Lin (177139)
Erin Mangan (5424785)
Hubert van Hoogstraten (5079860)
Gerd Burmester (52016)

June 2018

Table S1. LSM changes in RAID individual domain scores from baseline to week 24 with sarilumab 200Â ...

Additional file 7: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (HumiraÂŽ) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

Mean change from baseline in HAQ-DI by visit (ITT population). Abbreviations: Adalimumab-EU adalimum...

Additional file 6: of A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Roy Fleischmann (96247)
Rieke Alten (52012)
Margarita Pileckyte (5636498)
Kasia Lobello (3429245)
Steven Hua (5567111)
Carol Cronenberger (5636501)
Daniel Alvarez (5636504)
Amy Bock (5636507)
K. Sewell (5614937)

August 2018

DAS28–4(CRP) of less than 2.6 and ACR/EULAR remission by study visit (ITT population). Abbreviations...

Additional file 3: of Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study

Joshua Wallach (4741575)
Oriana Ciani (4485976)
Alison Pease (4991474)
Gregg S. Gonsalves (731654)
Harlan Krumholz (3401270)
Rod Taylor (25312)
Joseph Ross (3435704)

March 2018

Table S1. Pivotal trials with at least one postapproval trial with a patient-relevant outcome. (XLSX...

Additional file 1: of A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Stanley Cohen (411535)
Rieke Alten (52012)
Hideto Kameda (3399878)
Tomas Hala (5567096)
Sebastiao Radominski (5567099)
Muhammad Rehman (5567102)
Ramesh Palaparthy (4951276)
Karl Schumacher (5567105)
Susanne Schmitt (5567108)
Steven Hua (5567111)
Claudia Ianos (5567114)
K. Sewell (5614937)

July 2018

Supplementary methods and results, supplementary figures and figure legends, and supplementary table...

Additional file 4: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Mark Genovese (3442910)
Rene Westhovens (11539)
Luc Meuleners (4996577)
Annegret Van der Aa (4996583)
Pille Harrison (4996580)
Chantal Tasset (4996586)
Arthur Kavanaugh (2683)

March 2018

Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical di...

Additional file 1: of Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

Flora Elwes (4805568)
Shyamanga Borooah (491949)
Peter Aspinall (4805562)
Peng Sim (4805571)
Cheng Loo (4805565)
Ana-Maria Armbrecht (4805574)
Baljean Dhillon (4001)
Peter Cackett (4805559)

January 2018

Supplementary data. Correlated component regression analysis examining the predictors of change in B...

Additional file 1: Table S1. of Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors

Marie-Laure Golinski (786439)
Thibault Vandhuick (3441770)
Céline Derambure (786435)
Manuel Fréret (786436)
Matthieu Lecuyer (3441773)
Clément Guillou (786434)
Martine Hiron (3441767)
Olivier Boyer (211211)
Xavier Le Loët (408285)
Olivier Vittecoq (408284)
Thierry Lequerré (786441)

December 2015

Clinical and biological characteristics of rheumatoid arthritis (RA) patients treated with adalimuma...

Additional file 1: of A comparison of analytic approaches for individual patient data meta-analyses with binary outcomes

Doneal Thomas (3269046)
Robert Platt (507752)
Andrea Benedetti (139371)

February 2017

Median (Interquartile range (IQR)) absolute bias (%) for treatment effect, Î˛1 for different approac...

Additional file 1: of The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study

Anna O’Connor (3117774)
Carter Thorne (3508292)
Hyeon Kang (3508295)
Diane Tin (786343)
Janet Pope (3464090)

August 2016

Comparison of mean change in outcome measurement scores between early period (0–6 weeks) and late pe...

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Abstract

Extracted data

Additional file 1: of Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

Abstract

Extracted data

Related items

Related items